BUZZ-Aurinia Pharmaceuticals Inc: Positive kidney drug study
** Canadian drug maker's U.S. listed shares up 22 pct at $2.67; shares rise as much as 51 pct to $3.30 earlier, their biggest percentage gain in more than 2 years
** Says its experimental drug, Voclosporin, reduced excessive protein in urine by 25 pct in patients with lupus nephritis at 8 weeks of treatment
** Condition of excessive protein in urine, or Proteinuria, indicates a significant risk of renal disease
** Voclosporin is being studied as a potential treatment for lupus nephritis, or an inflammation of the kidneys
** Up to Friday's close, stock had fallen 37 pct in the past 12 months
© Thomson Reuters 2017 All rights reserved.